ROR1 Update: Does anyone know if there are any... - CLL Support

CLL Support

23,094 members39,666 posts

ROR1 Update

DaleFL profile image
15 Replies

Does anyone know if there are any preliminary results from any of the clinical trials involving ROR1? From what I understand, ROR1 is found on 90% or so if CLL and very little on healthy cells. I heard there is an anti-ROR1 medication in at least one clinical trial, and another trial is being planned to combine the anti-ROR1 medication with another medication to provide a synergistic effect. It seems very promising, but I was wondering if any preliminary results are available from single agent study using the anti-ROR1 medication. Thanks.

Written by
DaleFL profile image
DaleFL
To view profiles and participate in discussions please or .
Read more about...
15 Replies
Cllcanada profile image
CllcanadaTop Poster CURE Hero

The monoclonal is called cirmtuzumab (ROR1) and it is starting early trials with combinations...

Here is the latest from August 2017

lymphomahub.com/medical-inf...

Cirmtuzumab

oncternal.com/Pipeline/Cirm...

Here is the clinical trial which should open later this fall

clinicaltrials.gov/ct2/show...

MDAnderson has an ROR1 CAR T cell and I recall they have treated one patient... these trials are very early

mdanderson.org/patients-fam...

Justasheet1 profile image
Justasheet1 in reply to Cllcanada

Chris,

It looks like the combo is Ibrutinib and cirmtuzamab.

Hopefully, venetoclax is next.

Jeff

gemit2000 profile image
gemit2000 in reply to Cllcanada

I remember Chaya @ CLLTopics.org speaking about ROR-1 with CAR-T and remember it made sense to me the way she explained how U of Penn's T-Cells targeted B-cells with CD19 meaning it attacked healthy B-cells too, whereas with the ROR-1 approach @ MD Anderson the target was only cancer cells. I'm sure it's not as simple as my takeaway, that MDA's method was superior, but I remember I wanted to follow the ROR-1 approach. In any case it sounds like things didn't all go smoothly @ MDA since she wrote this in 2012 & as you say it's still very early.

updates.clltopics.org/4544-...

DaleFL profile image
DaleFL in reply to Cllcanada

Thank you so much for the detailed response. You answered my question. I pulled up the study and it states:

“Study Status Not Accepting”. Do you know what “not accepting” means? Does that mean the study has been terminated? Thanks again for all the info. :)

Cllcanada profile image
CllcanadaTop Poster CURE Hero in reply to DaleFL

Not sure.. I think its in limbo with a rethink taking place... just my guess...

If it was terminated it would say that...

gemit2000 profile image
gemit2000 in reply to DaleFL

After looking up cirmtuzumab & finding the Kipp's quote I shared with you, I realized why his quote is included on the company website - he's the one directing its clinical trials. I noticed he directed a prior (ongoing) study with dates of 2014 to 2017 for cirmtuzumab monotherapy. Perhaps they're waiting for that one to end before starting the combination trial (despite showing start date of Aug. 2017). I'd contact alphastemcellclinic@ucsd.edu to get all your questions answered.

Funny but being possibly close to treatment, I decided to search the other day for combination therapy trials and the only one I found with previously untreated subjects eligible was also at UCSD - an Imbruvica/Gazyva trial. I corresponded back and forth with them and they were very helpful.

- gene

DaleFL profile image
DaleFL in reply to gemit2000

I am anxious to find out what the results are. I think I will contact them. Thank you.

Cllcanada profile image
CllcanadaTop Poster CURE Hero in reply to DaleFL

All the Phase 1 data is available...

clinical-lymphoma-myeloma-l...

DaleFL profile image
DaleFL in reply to Cllcanada

Thank you. That is what I was looking for. :)

Fcancer profile image
Fcancer

There's another ror1 small molecule coming but won't go into phase one til next year the way it looks. Interesting read anyway and apparently they are now testing against solid tumours too (still in mice though). They have previously done some tests together with MD Anderson against ror1-bearing cancer cells in Richter's. I know this is not what the question was but I still find this very interesting and thought you might too. This link doesn't seem to work on phones - or maybe just my phone - just computors. feed.ne.cision.com/wpyfs/00...

Cllcanada profile image
CllcanadaTop Poster CURE Hero in reply to Fcancer

Might try this link,,

mb.cision.com/Main/1190/236...

DaleFL profile image
DaleFL in reply to Fcancer

Thank you so much. I am very interested in learning about all the new meds that are being researched. 🙂

Hoffy profile image
Hoffy

I recently saw Dr. Choi of UC San Diego speak on this. Big picture the ROR1 anti-body has done well in the first safety clinical trials. The results are good but the goal was more for safety so the strength is still to be determined . Juno out of Seattle is supposed to be closer on a car – T trial with ROR1 anti-body .

The Car-t trial I see as very exciting given that it would only theoretically attack cancer cells

Also UC San Diego is supposed to be starting a trial with Imbruica plus the ROR1 antibiotic .

DaleFL profile image
DaleFL in reply to Hoffy

Thank you. I appreciate your response. Is Dr. Choi your doctor?

Hoffy profile image
Hoffy in reply to DaleFL

Yes, He is a good guy!

Not what you're looking for?

You may also like...

Richter’s Transformation - Preliminary results of the clinical trial with Mosunetuzumab

Preliminary results of the clinical trial with clinical Mosunetuzumab at the ASH2019 congress. The...

Update

Hi all, just a quick update on me - I've moved to London from Melbourne to enter a phase 1...

STATIC Ibrutinib trial (FLAIR follow on) update for UK members

The STATIC team have released an update which is on the CLL Support website. In brief, there will...

LOXO-305 UPDATE 7 CYCLES COMPLETE

A while back I posted some results from my LOXO-305 clinical trial. I am now into my 8th 28 day...

Update on Oxford...

Been a busy couple of days since I got back on Friday, from my meeting with Anna Schur on Thursday,...